0
Skip to Content
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
Folder: ABOUT
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Folder: GET INVOLVED
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Folder: RESEARCH
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Folder: NEED HELP?
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Northeast, Connecticut Julia Travagline 11/20/24 Northeast, Connecticut Julia Travagline 11/20/24

Uncovering the role of chromosome 21 in Down syndrome-associated leukemias

Uncovering the role of chromosome 21 in Down syndrome-associated leukemias

Dr. Jason Sheltzer, Ph.D. – Yale University, New Haven, CT

Read More
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Dr. Jamie Anastas, Ph.D. – Baylor College of Medicine, Houston, TX

Read More
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
New York, Northeast Julia Travagline 11/20/24 New York, Northeast Julia Travagline 11/20/24

The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

Dr. lannis Aifantis, Ph.D. – New York University Grossman School of Medicine, New York, NY

Read More
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

CAR gamma delta T cell-based multi-pronged immunotherapy for AML

CAR gamma delta T cell-based multi-pronged immunotherapy for AML

Dr. Norihiro Watanabe, Ph.D. – Baylor College of Medicine

Read More
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Midwest, Michigan Julia Travagline 11/20/24 Midwest, Michigan Julia Travagline 11/20/24

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI

Read More
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Northeast, Washington D.C. Julia Travagline 11/20/24 Northeast, Washington D.C. Julia Travagline 11/20/24

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Dr. Yanxin Pei, M.D. – Children's Research Institute (CNMC), Washington, D.C.

Read More
Validating PRL2 as a New Therapeutic Target in T-ALL
Midwest, Illinois Julia Travagline 11/20/24 Midwest, Illinois Julia Travagline 11/20/24

Validating PRL2 as a New Therapeutic Target in T-ALL

Validating PRL2 as a New Therapeutic Target in T-ALL

Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Read More
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
International, Israel Julia Travagline 11/20/24 International, Israel Julia Travagline 11/20/24

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma

Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel

Read More
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Northeast, New York Julia Travagline 11/20/24 Northeast, New York Julia Travagline 11/20/24

The Role of S100A8/A9-IL6R in B-ALL Chemoresistance

The Role of S100A8/A9-IL6R in B-ALL Chemoresistance

Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY

Read More

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark